TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10931101
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose short synacthen test (HDT, 250 microgram)
Study: 10931101
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose short synacthen test (LDT, 1 microgram)
Study: 8147961
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (1500 mg RE/d)
Study: 3092269
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 30 mg
Study: 3092269
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 100 mg
Study: 31718953
Drug: Prasugrel 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 3.75 mg once daily
Study: 30340503
Drug: Aerobic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic and resistance exercise intervention (moderate-vigorous, 65-85% heart rate maximum, thrice weekly for 16 weeks)
Study: 24758077
Drug: Sulfasalazine Enteric-coated
Normalized name: sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine Enteric-coated Tablet (SECT), 0.5 g three times daily for 3 months (Control)
Study: 23047470
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ciprofloxacin 500 mg
Study: 23047470
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of ciprofloxacin 500 mg
Study: 20547163
Drug: Propranolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (up to 320 mg/day)
Study: 17340594
Drug: Androgen suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen suppression therapy (AST) and radiation therapy (RT) with 70 Gy and 6 months of AST
Study: 15827107
Drug: GH (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.5 mg/d)
Study: 15827107
Drug: GH (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.5 mg/d) and Testosterone (250 mg) combined
Study: 9865428
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (1.01 mg/kg/day)
Study: 9865428
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (2.01 mg/kg/day)
Study: 9865428
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (0.16 mg/kg/day)
Study: 7885123
Drug: Oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral captopril (6.25 mg initial dose, 12.5 mg 2 hours later, and then 12.5 mg three times daily)
Study: 2195936
Drug: Once-daily (OD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (OD) theophylline therapy administered in the evening at 8:00 P.M.
Study: 2195936
Drug: Conventional twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional twice-daily (TD) theophylline therapy administered at 8:00 A.M. and 8:00 P.M.
Study: 484815
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia (1.5 mg/kg bupivacaine)
Study: 25887977
Drug: Repeated treatment
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated treatment with praziquantel and albendazole four times a year
Study: 25887977
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose treatment with praziquantel and albendazole once a year
Study: 17724558
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy twice a week for 4 weeks followed by stretching exercises
Study: 17724558
Drug: Stretching 5
Normalized name: BANDAGE,STRETCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching 5 times a week for 4 weeks followed by manual therapy
Study: 16202254
Drug: Sibutramine tablet
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine tablet (10-20 mg/day for 24 weeks)
Study: 16202254
Drug: Sibutramine capsule
Normalized name: sibutramine Oral Capsule
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine capsule (10-20 mg/day for 24 weeks)
Study: 9213594
Drug: Acute allograft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute allograft rejection treatment
Study: 2012051
Drug: Ranitidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administration
Study: 2012051
Drug: Ranitidine non-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine non-administration (Control)
Study: 20183664
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and FLX
Study: 20183664
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (CBT, FLX, Combination, Placebo)
Study: 15182114
Drug: Telmisartan therapy
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan therapy (40-80 mg once daily)
Study: 12455252
Drug: Family medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family medicine preceptor
Study: 12455252
Drug: General internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: General internal medicine preceptor
Study: 7653792
Drug: Enoximone (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (1.0 mg/kg)
Study: 7653792
Drug: R80122 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: R80122 (0.3 mg/kg)
Study: 2702910
Drug: Hypoglycemia (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (50 mg/dl)
Study: 2702910
Drug: Normoglycemia (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemia (100 mg/dl)
Study: 2702910
Drug: Hyperglycemia (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (300 mg/dl)
Study: 362207
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (400 to 800 micrograms per day in divided doses)
Study: 362207
Drug: Alternate-day prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternate-day prednisone (20 to 40 mg on alternate mornings)
Study: 362207
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate and alternate-day prednisone (used together)
Study: 362207
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (7 children requiring only non-corticosteroid medication)
Study: 21667021
Drug: atRA treatment
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atRA treatment
Study: 17130503
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 or 300 mg once daily)
Study: 7855186
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment for 5 weeks after a 1-week wash-out and 1-week placebo period.
Study: 25955823
Drug: Basic body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic body awareness therapy (BAT)
Study: 23521461
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of contrast agent mixed with 2% mepivacaine
Study: 23521461
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received contrast agent only
Study: 20876826
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about the Drug Burden Index (DBI) provided to general practitioners (GPs) via a letter and phone call, prompting cessation or dose reduction of anticholinergic and sedative medications.
Study: 12113193
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment for ductal carcinoma in situ (DCIS)
Study: 7993148
Drug: Aspirin (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (at least 95% adherence)
Study: 7993148
Drug: Aspirin (taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (taking < 50% of study tablets)
Study: 3180636
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide gel, 8 gm t.i.d.
Study: 19270030
Drug: Parent-Scored PSC
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Scored PSC administration
Study: 19270030
Drug: Staff-Scored PSC
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Staff-Scored PSC administration
Study: 17097958
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (group 1)
Study: 17097958
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment (group 0)
Study: 15271745
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block (SSB) with 10 mL of 0.25% bupivacaine
Study: 15271745
Drug: Intraarticular local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular local anesthetic (IA) with 20 mL of 0.25% bupivacaine
Study: 15271745
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block (ISB) with 20 mL of 0.25% bupivacaine
Study: 11720825
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (neoadjuvant chemotherapy, Patey mastectomy, postoperative radiotherapy and adjuvant hormone therapy)
Study: 9071898
Drug: Initial hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial hormone therapy
Study: 11720825
Drug: Both therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapy groups
Study: 7895951
Drug: Hyperglycaemic clamping
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperglycaemic clamping (plasma glucose approximately 15 mmol/l) with somatostatin suppression of insulin secretion
Study: 7895951
Drug: Euglycaemic clamping
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Euglycaemic clamping (plasma glucose approximately 5 mmol/l) with somatostatin infusion
Study: 28603901
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (50 mg topical gel)
Study: 25078052
Drug: Outpatient misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outpatient misoprostol administration (800 mcg intra-vaginally, eight hourly, maximum of three doses)
Study: 25078052
Drug: Inpatient misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inpatient misoprostol administration (800 mcg intra-vaginally, eight hourly, maximum of three doses)
Study: 25078052
Drug: Outpatient misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outpatient misoprostol administration
Study: 25078052
Drug: Inpatient misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inpatient misoprostol administration
Study: 25078052
Drug: Both outpatient
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both outpatient and inpatient misoprostol administration
Study: 21861719
Drug: Cinnamon 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon 1,200 mg/day
Study: 19332203
Drug: Triple-antiplatelet therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-antiplatelet therapy with cilostazol, aspirin, and clopidogrel
Study: 19332203
Drug: Dual-antiplatelet treatment
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet treatment with aspirin and clopidogrel
Study: 15367413
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² followed by epirubicin 80 mg/m² (group A)
Study: 15367413
Drug: Paclitaxel followed
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel followed by carboplatin at an AUC of 6 mg x min/ml (group B)
Study: 9195203
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous dexamethasone (1 mg/m2)
Study: 9195203
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral dexamethasone (2 mg)
Study: 9195203
Drug: GH-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-releasing hormone
Study: 3557731
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg labetalol daily for eight weeks
Study: 3557731
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg labetalol daily for eight weeks
Study: 29753994
Drug: Daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily calorie restriction diet (22% daily reduction in energy needs)
Study: 29753994
Drug: Both calorie
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both calorie restriction diets (daily and intermittent)
Study: 27769310
Drug: CueS wristband
Approvals — FDA: no, EMA: no, PMDA: no
Description: CueS wristband providing 'live' feedback towards pre-set movement goals during a 4-week upper limb therapy programme.
Study: 27769310
Drug: Sham CueS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham CueS wristband that monitors upper limb activity but provides no feedback during a 4-week upper limb therapy programme.
Study: 25539929
Drug: B-type natriuretic
Normalized name: B-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-type natriuretic peptide (BNP) 3.0 pmol·kg(‐1)·min(‐1) during a continuous infusion lasting for 4 h
Study: 23033237
Drug: Open-loop therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-loop therapy
Study: 17341661
Drug: Ambulatory postremission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory postremission strategy (6 consolidation cycles administered monthly in outpatients)
Study: 15625656
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU/day) and pioglitazone (30 mg/day)
Study: 11171891
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus air blanket therapy (n = 113)
Study: 11171891
Drug: Acetaminophen alone
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alone (n = 107)
Study: 7851271
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion to inhibit tubular reabsorption (TR) of transferrin
Study: 28671553
Drug: High HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High HBV viral load (>6 log IU/ml) patients in LVD group
Study: 28671553
Drug: High HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High HBV viral load (>6 log IU/ml) patients in ETV group
Study: 22252354
Drug: GAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAA supplementation at 0.6 g/kg
Study: 22252354
Drug: GAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAA supplementation at 1.2 g/kg
Study: 22252354
Drug: 1.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/kg GAA
Study: 8095137
Drug: Exposure in
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure in vivo followed by cognitive therapy
Study: 8095137
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy followed by exposure in vivo
Study: 8768511
Drug: Cognitive‐behavioral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral treatment integrating both strategies from the start
Study: 8768511
Drug: Cognitive-exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-exposure treatment
Study: 6981695
Drug: Inhaled cephaloridine
Normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cephaloridine
Study: 6981695
Drug: No inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhaled antibiotic (Control)
Study: 25943670
Drug: Internal cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal cooling (ICE, 7.5 g/kg ice slurry ingestion)
Study: 19363967
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg, PO single dose)
Study: 19363967
Drug: Placebo (tinted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tinted oil in clear capsule)
Study: 9862086
Drug: Caffeine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.2 mg/kg, similar to a serving of ground coffee)
Study: 9862086
Drug: Caffeine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.2 mg/kg, 86 mg, 172 mg, 258 mg total across three doses)
Study: 7604149
Drug: IV yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV yohimbine (0.4 mg/kg)
Study: 7405249
Drug: Dimeditiapramine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimeditiapramine (1 mg/kg body weight, single intravenous dose)
Study: 28958851
Drug: Liraglutide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3.0 mg, subcutaneous, escalated by 0.6 mg/day for 5 weeks, continued until week 16)
Study: 28958851
Drug: Liraglutide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3.0 mg, subcutaneous)
Study: 23785020
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (1st week 0.01 mg/day/kg, 2nd week 0.02 mg/day/kg, 3rd week 0.03 mg/day/kg)
Study: 23785020
Drug: GH receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH receptor antagonist (Pegvisomant) treatment (1st week 10 mg/day, last 2 weeks 15 mg/day)
Study: 14666956
Drug: Structured care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured care with atorvastatin (10-80 mg/day, mean 23.7 mg/day)
Study: 14666956
Drug: Structured care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured care with atorvastatin
Study: 8838966
Drug: Oral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ampicillin 1 g every 8 hours for 7 days
Study: 1283893
Drug: Finasteride therapy
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride therapy for one week
Study: 31138273
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving oral health care as usual
Study: 29985459
Drug: Nurse-led repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led repeated prescription (NRP)
Study: 1637611
Drug: i.v. tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. tenoxicam 20 mg
Study: 9113635
Drug: High-AA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-AA diet (1.5 g/d)
Study: 8368552
Drug: Dezocine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine (5 mg)
Study: 3752420
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with birch pollen extract (20 X 10(6) BU monthly, daily for seven consecutive days every month or once weekly)
Study: 3752420
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with birch pollen extract (more than 2 X 10(5) BU monthly)
Study: 3752420
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with birch pollen extract
Study: 31394910
Drug: Yoga (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga (twice a week for 8 weeks)
Study: 24718821
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of radiotherapy (>30 gy to <60 gy)
Study: 14981214
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of methylphenidate (0.5 mg/kg)
Study: 14981214
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of methylphenidate (0.5 mg/kg)
Study: 14981214
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of methylphenidate (1.0 mg/kg)
Study: 11182173
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus 25 mg i.v. of canreonate (1 mg/h for the 1st 72 h and then orally 25 mg/day)
Study: 9638313
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (GS) at a daily dose of 1,500 mg for 4 weeks